Research Article

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Master of Science of Virology, Iran University of Medical Sciences, Tehran, Iran

Zinat Hosseini

School of Medicine, Iran University of Medical Sciences, Tehran, Iran

General Medical Student, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Search for more papers by this author

Poupak Mortazkar

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

PhD Student of Virology, Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Search for more papers by this author

Khadijeh Khanaliha

Research Center of Pediatric Infectious Diseases, Institute of Immunology & Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran

Assistant Professor of Parasitology, Research Center of Pediatric Infectious Diseases, Institute of Immunology & Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran

Search for more papers by this author

Maryam Esghaei

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Associate Professor of Virology, Iran University of Medical Sciences, Tehran, Iran

Search for more papers by this author

Atousa Fakhim

Department of Architectural Engineering, Faculty of Engineering, Islamic Azad University, South Tehran Branch, Tehran, Iran

Student of Architectural Engineering, Islamic Azad University, South Tehran Branch, Tehran, Iran

Search for more papers by this author

Farah Bokharaei-Salim

*Author for correspondence: Tel.: +98 216 604 7831; Fax: +98 216 604 7831;

E-mail Address: bokharaei.f@iums.ac.ir

;

E-mail Address: bokharaeifarah@gmail.com

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Assistant Professor of Virology, Iran University of Medical Sciences, Tehran, Iran

Search for more papers by this author

Published Online:24 Apr 2020https://doi.org/10.2217/fvl-2019-0066

View article

Abstract

Aim: HIV-infected patients risk coinfection with HBV and HCV. This study aimed to investigate molecular epidemiology of HBV and HCV coinfection in Iranian HIV-infected individuals. Materials & methods: In this cross-sectional study, serological markers of HBV and HCV infection (hepatitis B surface antigen [HBsAg], hepatitis B e-antigen [HBeAg], hepatitis B e-antibody [HBeAb] and hepatitis B core antibody [HBcAb]) and anti-HCV antibodies [anti-HCV Abs] were tested in 198 Iranian HIV-infected patients. From plasma, HBV viral load was determined using COBAS TaqMan 48, and HCV-RNA was detected by reverse transcriptase-nested PCR. Results: 85 out of 198 (42.9%) patients were anti-HCV Ab positive and 42/198 (21.2%) had detectable HCV-RNA. Eight (4.0%) had traceable HBV-DNA. All these patients were infected by HBV genotype D. 55 (27.8%) were HBcAb positive. Nine (4.4%) were HBsAg and anti-HCV Ab positive. Conclusion: None were HIV-RNA/HCV-RNA/HBV-DNA positive, 21.2% were HIV-RNA/HCV-RNA positive and 4.0% were HIV-RNA/HBV-DNA positive. Therefore, studies on diagnosing these infections in HIV-infected individuals may be valuable.

Keywords:

References

1. Zulfiqar HF, Javed A, Sumbal et al. HIV diagnosis and treatment through advanced technologies. Front. Public Health. 5, 32 (2017).
MedlineGoogle Scholar
2. World Health Organization Global Health Observatory. HIV/AIDS. (2018). www.who.int/gho/hiv/en/
Google Scholar
3. Tavakoli A, Karbalaie Niya MH, Keshavarz M et al. Current diagnostic methods for HIV. Future Virol. 12(3), 141–155 (2017).
CASGoogle Scholar
4. Lin S, Zhang YJ. Interference of apoptosis by hepatitis B virus. Viruses 9(8), 230 (2017).
Google Scholar
5. Fujiwara K, Matsuura K, Matsunami K, Iio E, Nojiri S. Characterization of hepatitis B virus with complex structural variations. BMC Microbiol. 18(1), 202 (2018).
Medline CASGoogle Scholar
6. Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS 31(15), 2035–2052 (2017).
MedlineGoogle Scholar
7. Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30(12), 2212–2219 (2012).
Medline CASGoogle Scholar
8. Lingala S, Ghany MG. Hepatitis B: screening, awareness, and the need to treat. Fed. Pract. 33(Suppl. 3), S19–S23 (2016).
MedlineGoogle Scholar
9. Salehi-Vaziri M, Sadeghi F, Hashiani AA, Fesharaki MG, Alavian SM. Hepatitis B virus infection in the general population of Iran: an updated systematic review and meta-analysis. Hepat. Mon. 16(4), e35577 (2016).
MedlineGoogle Scholar
10. Rho J, Ryu JS, Hur W et al. Hepatitis C virus (HCV) genotyping by annealing reverse transcription-PCR products with genotype-specific capture probes. J. Microbiol. 46(1), 81–87 (2008).
Medline CASGoogle Scholar
11. Borgia SM, Hedskog C, Parhy B et al. Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J. Infect. Dis. 218(11), 1722–1729 (2018).
MedlineGoogle Scholar
12. Nouhin J, Iwamoto M, Prak S et al. Molecular epidemiology of hepatitis C virus in Cambodia during 2016–2017. Sci. Rep. 9(1), 1–9 (2019).
Medline CASGoogle Scholar
13. Thornton AC, Jose S, Bhagani S et al. Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. AIDS 31(18), 2525–2532 (2017).
MedlineGoogle Scholar
14. Merat S, Rezvan H, Nouraie M et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int. J. Infect. Dis. 14(Suppl. 3), e113–e116 (2010).
MedlineGoogle Scholar
15. Sarvari J, Moattari A, Pirbonyeh N, Moini M, Hosseini SY. The impact of IFN‐γ gene polymorphisms on spontaneous clearance of HCV infection in Fars Province, Southern of Iran. J. Clin. Lab. Anal. 30(4), 301–307 (2016).
Medline CASGoogle Scholar
16. Afsharzadeh F, Bokharaei-Salim F, Esghaei M et al. The presence of autoantibodies to cytoplasmic rod and ring particles in the serum of patients with chronic hepatitis C virus infection. Hepat. Mon. 16(12), e42388 (2016).
MedlineGoogle Scholar
17. Merchante N, Rodríguez-Arrondo F, Revollo B et al. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. AIDS 32(11), 1423–1430 (2018).
Medline CASGoogle Scholar
18. Thio CL, Seaberg EC, Skolasky R Jr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360(9349), 1921–1926 (2002).
MedlineGoogle Scholar
19. Hoffmann CJ, Seaberg EC, Young S et al. Hepatitis B and long-term HIV outcomes in co-infected HAART recipients. AIDS 23(14), 1881 (2009).
MedlineGoogle Scholar
20. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 18(15), 2039–2045 (2004).
MedlineGoogle Scholar
21. Mendes-Correa M, Nunez M. Management of HIV and hepatitis virus coinfection. Expert Opin. Pharmacother. 11(15), 2497–2516 (2010).
Medline CASGoogle Scholar
22. Salmon‐Ceron D, Nahon P, Layese R et al. Human immunodeficiency virus/hepatitis C Virus (HCV) co‐infected patients with cirrhosis are no longer at higher risk for hepatocellular carcinoma or end‐stage liver disease as compared to HCV mono‐infected patients. Hepatology 70(3), 939–954 (2019).
Medline CASGoogle Scholar
23. Kilonzo SB, Gunda DW, Kashasha F, Mpondo BC. Liver fibrosis and hepatitis B coinfection among ART naive HIV-infected patients at a tertiary level hospital in Northwestern Tanzania: a cross-sectional study. J. Trop. Med. 2017, 5629130 (2017).
MedlineGoogle Scholar
24. Tajik Z, Keyvani H, Bokharaei-Salim F et al. Detection of hepatitis B virus covalently closed circular DNA in the plasma of Iranian HBeAg-negative patients with chronic hepatitis B. Hepat. Mon. 15(9), e30790 (2015).
MedlineGoogle Scholar
25. Tajik Z, Bokharaei-Salim F, Ghorbani S et al. Detection of HBV genome in the plasma and peripheral blood mononuclear cells of Iranian HBsAg negative patients with HIV infection: occult HBV infection. Arch. Virol. 163(6), 1559–1566 (2018).
Medline CASGoogle Scholar
26. Bokharaei-Salim F, Keyvani H, Monavari SH et al. Distribution of hepatitis B virus genotypes in azerbaijani patients with chronic hepatitis B infection. Hepat. Mon. 14(12), e25105 (2014).
MedlineGoogle Scholar
27. Sadeghi F, Salehi-Vaziri M, Ghodsi SM et al. Prevalence of JC polyomavirus large T antigen sequences among Iranian patients with central nervous system tumors. Arch. Virol. 160(1), 61–68 (2015).
Medline CASGoogle Scholar
28. Pohjanpelto P, Lappalainen M, Widell A, Asikainen K, Paunio M. Hepatitis C genotypes in Finland determined by RFLP. Clin. Diagn. Virol. 7(1), 7–16 (1996).
Medline CASGoogle Scholar
29. Bokharaei-Salim F, Keyvani H, Monavari SH et al. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J. Med. Virol. 83(6), 989–995 (2011).
MedlineGoogle Scholar
30. Smith CJ, Ryom L, Weber R et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 384(9939), 241–248 (2014).
MedlineGoogle Scholar
31. Javadi A, Ataei B, Kassaian N, Nokhodian Z, Yaran M. Co-infection of human immunodeficiency virus, hepatitis C and hepatitis B virus among injection drug users in Drop in centers. J. Res. Med. Sci. 19(Suppl. 1), S17–S21 (2014).
MedlineGoogle Scholar
32. Platt L, Easterbrook P, Gower E et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet. Infect. Dis. 16(7), 797–808 (2016).
MedlineGoogle Scholar
33. Shahbazi M, Farnia M, Rahmani K, Moradi G. Trend of HIV/AIDS prevalence and related interventions administered in Prisons of Iran − 13years’ experience. Iran. J. Public Health 43(4), 471–479 (2014).
MedlineGoogle Scholar
34. Naziri H, Baesi K, Moradi A et al. Antiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014. Arch. Virol. 9(161), 2503–2509 (2016).
Google Scholar
35. National AIDS Committee Secretariat, Ministry of Health and Medical Education. Islamic Republic of Iran AIDS Progress Report. (2015). www.unaids.org/sites/default/files/country/documents/IRN_narrative_report_2015.pdf
Google Scholar
36. Vahabpour R, Bokharaei-Salim F, Kalantari S et al. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. Arch. Virol. 162(6), 1477–1485 (2017).
Medline CASGoogle Scholar
37. Afzali H, Momen-Heravi M, Farokhzad A. Epidemiological distribution and genotype characterization of the hepatitis C virus among HIV patients in Kashan, Iran. Hepat. Mon. 16(7), e30459 (2016).
MedlineGoogle Scholar
38. Alipour A, Rezaianzadeh A, Hasanzadeh J, Rajaeefard A, Davarpanah M, Hasanabadi M. High prevalence of HCV coinfection in HIV-infected individuals in Shiraz, Islamic Republic of Iran. East. Mediterr. Health J. 19(12), 975–981 (2013).
Medline CASGoogle Scholar
39. Bradshaw D, Matthews G, Danta M. Sexually transmitted hepatitis C infection: the new epidemic in MSM? Curr. Opin. Infect. Dis. 26(1), 66–72 (2013).
Medline CASGoogle Scholar
40. Stenkvist J, Nyström J, Falconer K, Sönnerborg A, Weiland O. Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals. J. Hepatol. 61(4), 957–961 (2014).
MedlineGoogle Scholar
41. Freitas SZ, Teles SA, Lorenzo PC et al. HIV and HCV coinfection: prevalence, associated factors and genotype characterization in the midwest region of Brazil. Rev. Inst. Med. Trop. Sao Paulo. 56(6), 517–524 (2014).
MedlineGoogle Scholar
42. Ponamgi SP, Rahamathulla S, Kumar YN et al. Prevalence of hepatitis C virus (HCV) coinfection in HIV infected individuals in south India and characterization of HCV genotypes. Indian J. Med. Microbiol. 27(1), 12–16 (2009).
Medline CASGoogle Scholar
43. Wu SZ, Wei JL, Xu B et al. Detection and analysis of hepatitis C virus in HIV-infected patients in the Guangxi province of China. Exp. Ther. Med. 13(3), 917–923 (2017).
Medline CASGoogle Scholar
44. Phusanti S, Manosudprasit K, Sungkanuparph S. Long-term liver diseases after initiation of antiretroviral therapy in HIV-infected patients with and without HBV or HCV coinfection. J. Int. Assoc. Provid. AIDS Care 16(2), 194–200 (2017).
MedlineGoogle Scholar
45. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 259(1), 65–73 (2006).
Google Scholar
46. Singh KP, Crane M, Audsley J, Lewin SR. HIV-Hepatitis B virus co-infection: epidemiology, pathogenesis and treatment. AIDS 31(15), 2035 (2017).
MedlineGoogle Scholar
47. Gandhi RT, Wurcel A, Lee H et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1− infected individuals. Clin. Infect. Dis. 36(12), 1602–1605 (2003).
Medline CASGoogle Scholar
48. Thomas DL, Cannon RO, Shapiro CN, Hook EW 3rd, Alter MJ, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J. Infect. Dis. 169(5), 990–995 (1994).
Medline CASGoogle Scholar
49. Singal AG, Lampertico P, Nahon P. Epidemiology of hepatocellular carcinoma: New trends. J Hepatol. 72(2), 250–261 (2020).
Medline CASGoogle Scholar
50. Khodabandehloo M, Roshani D, Sayehmiri K. Prevalence and trend of hepatitis C virus infection among blood donors in Iran: a systematic review and meta-analysis. J. Res. Med. Sci. 18(8), 674–682 (2013).
MedlineGoogle Scholar
51. Saber HR, Tabatabaee SM, Abasian A et al. Incidence and residual risk of HIV, HBV and HCV infections among blood donors in Tehran. Indian J. Hematol. Blood Transfus. 33(3), 412–416 (2017).
MedlineGoogle Scholar
52. Lo Re V 3rd, Kallan MJ, Tate JP et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann. Intern. Med. 160(6), 369–379 (2014).
MedlineGoogle Scholar
53. Choy CY, Ang LW, Ng OT, Leo YS, Wong CS. Factors associated with hepatitis B and C co-infection among HIV-infected patients in Singapore, 2006–2017. Trop. Med. Infect. Dis. 4(2), 87 (2019).
Google Scholar
54. Rockstroh JK, Ingiliz P, Petersen J et al. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease. Antivir. Ther. 22(3), 225–236 (2017).
Medline CASGoogle Scholar
55. Ranin J, Salemovic D, Brmbolic B et al. Comparison of demographic, epidemiological, immunological, and clinical characteristics of patients with HIV mono-infection versus patients co-infected with HCV or/and HBV: a Serbian cohort study. Curr. HIV Res. 16(3), 222–230 (2018).
Medline CASGoogle Scholar
56. Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV coinfection prevalence in Iran-a systematic review and meta-analysis. PLoS ONE 11(3), e0151946 (2016).
MedlineGoogle Scholar
57. Lo Re V 3rd, Wang L, Devine S, Baser O, Olufade T. Hepatic decompensation in patients with HIV/hepatitis B Virus (HBV)/hepatitis C Virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy. Clin. Infect. Dis. 59(7), 1027–1031 (2014).
MedlineGoogle Scholar

Vol. 15, No. 3

Metrics

Downloaded 73 times

History

Received 13 June 2019

Accepted 20 February 2020

Published online 24 April 2020

Published in print March 2020

Information

Keywords

Acknowledgments

All the authors of this article are very grateful to those who volunteered to participate in this research.

Financial & competing interests disclosure

The current research was funded by Research Deputy of Iran University of Medical Sciences (IUMS), Tehran, Iran with Grant Number 8921215087. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

Ethical approval for this research was obtained from the local ethics committee of Iran University of Medical Sciences (IUMS), Tehran, Iran, that is accordance with Helsinki declaration (ethical code: IR.IUMS.FMD.REC 1396. 8921215087). All of the volunteers participating in this study were informed about this research prior to their enrollment. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download

Prevalence of HCV and/or HBV coinfection in Iranian HIV-infected patients

Abstract

References